EUVIMEDEUVIMED entdecken
Open Access

Clinical Epigenetic Therapies Disrupt Sex Chromosome Dosage Compensation in Human Female Cells

Agnieszka I Laskowski, Danielle A Fanslow, Erica D Smith, Steven T Kosak

Gender and the Genome · 2018

DOI: 10.1177/2470289718787106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gender and the Genome, 2018. Verfasst von Agnieszka I Laskowski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sex chromosome gene dosage compensation is required to ensure equivalent levels of X-linked gene expression between males (46, XY) and females (46, XX). To achieve similar expression, X-chromosome inactivation (XCI) is initiated in female cells during early stages of embryogenesis. Within each cell, either the maternal or paternal X chromosome is selected for whole chromosome transcriptional silencing, which is initiated and maintained by epigenetic and chromatin conformation mechanisms. With the emergence of small-molecule epigenetic inhibitors for the treatment of disease, such as cancer, the epigenetic mechanism underlying XCI may be inadvertently targeted. Here, we test 2 small-molecule epigenetic inhibitors being used clinically, GSK126 (a histone H3 lysine 27 methyltransferase inhibitor) and suberoylanilide hydroxamic acid (a histone deacetylase inhibitor), on their effects of the inactive X (Xi) in healthy human female fibroblasts. The combination of these modifiers, at subcancer therapeutic levels, leads to the inability to detect the repressive H3K27me3 modification characteristic of XCI in the majority of the cells. Importantly, genes positioned near the X-inactivation center ( Xic), where inactivation is initiated, exhibit robust expression with treatment of the inhibitors, while genes located near the distal ends of the X chromosome intriguingly exhibit significant downregulation. These results demonstrate that small-molecule epigenetic inhibitors can have profound consequences on XCI in human cells, and they underscore the importance of considering gender when developing and clinically testing small-molecule epigenetic inhibitors, in particular those that target the well-characterized mechanisms of X inactivation.

Schlagwörter

Stichwörter der Autor:innen

X-chromosome inactivationX-linked gene expressionX-linked gene regulationbiological sex and gene expressionenvironment and epigeneticsepigenetic inhibitorsgender-specific medicinegene dosage compensationsex-specific genetic architecture

Autor:innen und Institutionen

  • Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Laskowski, A. I., Fanslow, D. A., Smith, E. D., & Kosak, S. T. (2018). Clinical Epigenetic Therapies Disrupt Sex Chromosome Dosage Compensation in Human Female Cells. Gender and the Genome. https://doi.org/10.1177/2470289718787106

Vancouver

Laskowski AI, Fanslow DA, Smith ED, Kosak ST. Clinical Epigenetic Therapies Disrupt Sex Chromosome Dosage Compensation in Human Female Cells. Gender and the Genome. 2018. doi:10.1177/2470289718787106

BibTeX
@article{Laskowski2018,
  author = {Laskowski, Agnieszka I and Fanslow, Danielle A and Smith, Erica D and Kosak, Steven T},
  title = {Clinical Epigenetic Therapies Disrupt Sex Chromosome Dosage Compensation in Human Female Cells},
  journal = {Gender and the Genome},
  year = {2018},
  doi = {10.1177/2470289718787106}
}
Kostenlos starten →